JP2011503071A5 - ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 - Google Patents
ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 Download PDFInfo
- Publication number
- JP2011503071A5 JP2011503071A5 JP2010533126A JP2010533126A JP2011503071A5 JP 2011503071 A5 JP2011503071 A5 JP 2011503071A5 JP 2010533126 A JP2010533126 A JP 2010533126A JP 2010533126 A JP2010533126 A JP 2010533126A JP 2011503071 A5 JP2011503071 A5 JP 2011503071A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- topoisomerase inhibitor
- ovarian cancer
- nitrobenzamide
- iodo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims 10
- 206010033128 Ovarian cancer Diseases 0.000 title claims 9
- JWMYQGBWTXDELZ-UHFFFAOYSA-N 3-iodo-2-nitrobenzamide Chemical class NC(=O)C1=CC=CC(I)=C1[N+]([O-])=O JWMYQGBWTXDELZ-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 12
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 12
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 229960000303 topotecan Drugs 0.000 claims 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical group C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 4
- 108700020463 BRCA1 Proteins 0.000 claims 3
- 102000036365 BRCA1 Human genes 0.000 claims 3
- 101150072950 BRCA1 gene Proteins 0.000 claims 3
- 102000052609 BRCA2 Human genes 0.000 claims 3
- 108700020462 BRCA2 Proteins 0.000 claims 3
- 101150008921 Brca2 gene Proteins 0.000 claims 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 229950009429 exatecan Drugs 0.000 claims 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000005549 size reduction Methods 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Description
Claims (19)
- ４−ヨード−３−ニトロベンズアミド、又はその代謝物もしくは薬学的に許容しうる塩、及び少なくとも１つのトポイソメラーゼ阻害剤の、卵巣がんに罹患しているヒト患者における進行性卵巣がんの治療用の、医薬品の製造のための使用。
- ４−ヨード−３−ニトロベンズアミド、又はその代謝物、又はその薬学的に許容しうる塩、及び少なくとも１つのトポイソメラーゼ阻害剤が、別々の剤形で提供され、そして順次投与される、請求項１に記載の使用。
- ４−ヨード−３−ニトロベンズアミド、又はその代謝物、又はその薬学的に許容しうる塩、及び少なくとも１つのトポイソメラーゼ阻害剤が、別々の剤形で提供され、そして同時に投与される、請求項１に記載の使用。
- 卵巣がんは転移性である、請求項１〜３のいずれかに記載の使用。
- トポイソメラーゼ阻害剤はトポイソメラーゼＩ阻害剤である、請求項１〜３のいずれかに記載の使用。
- トポイソメラーゼ阻害剤はトポイソメラーゼII阻害剤である、請求項１〜３のいずれかに記載の使用。
- トポイソメラーゼ阻害剤は、トポテカン、イリノテカン、ルートテカン、エキサテカン
及びカンプトセシンからなる群より選ばれる、請求項１〜３のいずれかに記載の使用。 - トポイソメラーゼ阻害剤は、トポテカン、イリノテカン及びカンプトセシンからなる群より選ばれる、請求項１〜３のいずれかに記載の使用。
- トポイソメラーゼ阻害剤はカンプトセシン誘導体である、請求項１〜３のいずれかに記載の使用。
- カンプトセシン誘導体は、１０−ヒドロキシカンプトセシン、トポテカン、イリノテカン及び９−アミノカンプトセシンからなる群より選ばれる、請求項９に記載の使用。
- トポイソメラーゼ阻害剤はトポテカンである、請求項１〜３のいずれかに記載の使用。
- 卵巣腫瘍のサイズ縮小、転移の減少、完全寛解、部分寛解、安定、及び病理学的完全奏効からなる群より選ばれる少なくとも１つの治療効果をもたらす、請求項１〜３のいずれかに記載の使用。
- 卵巣がんは相同組換えＤＮＡ修復における欠損である、請求項１〜３のいずれかに記載の使用。
- 卵巣がんはＢＲＣＡ欠損である、請求項１〜３のいずれかに記載の使用。
- ＢＲＣＡ欠損は、ＢＲＣＡ１欠損、ＢＲＣＡ２欠損、又はＢＲＣＡ１及びＢＲＣＡ２両方の欠損である、請求項１４に記載の使用。
- トポイソメラーゼ阻害剤を、４−ヨード−３−ニトロベンズアミド又はその薬学的に許容しうる塩を、投与する前に、投与と同時に、又は投与後に投与する、請求項１に記載の使用。
- 卵巣がんは、上皮性腫瘍、胚細胞腫瘍又は間質細胞腫瘍である、請求項１〜３のいずれかに記載の使用。
- ４−ヨード−３−ニトロベンズアミド、又はその代謝物若しくは薬学的に許容しうる塩、及び少なくとも１つのトポイソメラーゼ阻害剤の、ＢＲＣＡ１又はＢＲＣＡ２に関連した進行性卵巣がんの治療用の、医薬品の製造のための使用。
- バイアルの組合せを含む剤形であって、第一バイアルは４−ヨード−３−ニトロベンズアミド、又はその代謝物若しくは薬学的に許容しうる塩を含み、そして第二バイアルは少なくとも１つのトポイソメラーゼ阻害剤を含む、進行性卵巣がんの治療のための、上記剤形。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98733507P | 2007-11-12 | 2007-11-12 | |
| US1236407P | 2007-12-07 | 2007-12-07 | |
| US5852808P | 2008-06-03 | 2008-06-03 | |
| PCT/US2008/012757 WO2009064444A2 (en) | 2007-11-12 | 2008-11-12 | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503071A JP2011503071A (ja) | 2011-01-27 |
| JP2011503071A5 true JP2011503071A5 (ja) | 2011-12-22 |
Family
ID=40623903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533126A Abandoned JP2011503071A (ja) | 2007-11-12 | 2008-11-12 | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090123419A1 (ja) |
| EP (1) | EP2217244A4 (ja) |
| JP (1) | JP2011503071A (ja) |
| KR (1) | KR20100102607A (ja) |
| CN (1) | CN101918003A (ja) |
| AU (1) | AU2008321382A1 (ja) |
| CA (1) | CA2705417A1 (ja) |
| CO (1) | CO6290649A2 (ja) |
| CR (1) | CR11486A (ja) |
| DO (2) | DOP2010000142A (ja) |
| EC (1) | ECSP10010235A (ja) |
| GT (1) | GT201000137A (ja) |
| IL (1) | IL205633A0 (ja) |
| MA (1) | MA32748B1 (ja) |
| MX (1) | MX2010005221A (ja) |
| NI (1) | NI201000084A (ja) |
| NZ (1) | NZ586123A (ja) |
| SG (1) | SG185954A1 (ja) |
| TN (1) | TN2010000209A1 (ja) |
| WO (1) | WO2009064444A2 (ja) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5177429B2 (ja) * | 2005-07-18 | 2013-04-03 | バイパー サイエンシズ，インコーポレイティド | 癌の治療 |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010504079A (ja) * | 2006-06-12 | 2010-02-12 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤を用いる疾病の治療方法 |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| EP2059802A4 (en) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF |
| CN101522609A (zh) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| US7994222B2 (en) | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN101888777A (zh) * | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
| WO2011133748A1 (en) * | 2010-04-21 | 2011-10-27 | University Of Medicine And Dentistry Of New Jersey | Treatments for cellular proliferative disorders and identification thereof |
| WO2011153382A1 (en) * | 2010-06-04 | 2011-12-08 | Bipar Sciences, Inc. | Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and platinum compound |
| WO2011153383A1 (en) * | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP2595618A1 (en) * | 2010-07-19 | 2013-05-29 | BiPar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| BR112013011135A2 (pt) | 2010-11-05 | 2016-08-02 | Zhejiang Hisun Pharm Co Ltd | ''composto,método para a preparação do composto,composição farmacêutica e uso do composto'' |
| WO2013076295A1 (en) * | 2011-11-25 | 2013-05-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for screening a brca1 loss-of-function in a subject suffering from a cancer |
| FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| US20160011220A1 (en) * | 2012-02-14 | 2016-01-14 | Purdue Pharma L.P. | Systems and Methods to Quantify Analytes in Keratinized Samples |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| TWI444358B (zh) * | 2012-07-09 | 2014-07-11 | Univ Chang Gung | 一種含有５－硝基苯之衍生物，透過抑制腫瘤細胞誘發血小板凝集反應作為癌症轉移治療方式 |
| US20140186293A1 (en) * | 2012-12-31 | 2014-07-03 | University Of Louisville Research Foundation, Inc. | Immunoglobulin-bound extracellular vesicles and uses thereof |
| SI2970878T1 (sl) | 2013-03-15 | 2019-02-28 | Truckee Applied Genomics, Llc | Postopki in reagenti za vzdrževanje preživetja rakavih celic v kirurško odstranjenem tkivu |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| CN114927178A (zh) * | 2015-06-12 | 2022-08-19 | 格尼亚Ip控股私人有限公司 | 患者和生物样本识别和追踪的方法和*** |
| WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| CA2993451A1 (en) | 2015-08-21 | 2017-03-02 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| WO2017151554A1 (en) * | 2016-02-29 | 2017-09-08 | Synta Pharmaceuticals Corp | Combination therapy for treatment of ovarian cancer |
| EP4302835A3 (en) * | 2016-06-29 | 2024-03-20 | Tesaro, Inc. | Methods of treating ovarian cancer |
| WO2018059437A1 (en) * | 2016-09-27 | 2018-04-05 | Beigene, Ltd. | Treatment cancers using combination comprising parp inhibitors |
| US11071726B2 (en) | 2016-11-02 | 2021-07-27 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |
| KR20190111116A (ko) * | 2017-02-06 | 2019-10-01 | 시티 오브 호프 | 암의 치료 |
| US20200061054A1 (en) * | 2017-02-28 | 2020-02-27 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor |
| JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ， インコーポレイテッド | 癌を処置する併用療法 |
| WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | METHODS OF TREATING GLIOBLASTOMA |
| WO2019005754A1 (en) * | 2017-06-26 | 2019-01-03 | The Cleveland Clinic Foundation | TREATMENT AGAINST CANCER |
| WO2019067991A1 (en) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND USES THEREOF |
| SG11202002862RA (en) | 2017-09-30 | 2020-04-29 | Tesaro Inc | Combination therapies for treating cancer |
| JP6915865B2 (ja) * | 2017-10-03 | 2021-08-04 | 学校法人 愛知医科大学 | Ｎｏ産生抑制剤及び固形腫瘍に対する転移・浸潤抑制剤 |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| US11590130B2 (en) | 2018-04-05 | 2023-02-28 | Noviga Research Ab | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer |
| EP3927841A1 (en) * | 2019-02-21 | 2021-12-29 | F. Hoffmann-La Roche AG | Improved nucleic acid target enrichment and related methods |
| US11704494B2 (en) | 2019-05-31 | 2023-07-18 | Ab Initio Technology Llc | Discovering a semantic meaning of data fields from profile data of the data fields |
| CN110600098A (zh) * | 2019-08-09 | 2019-12-20 | 广州中医药大学第一附属医院 | 一种临床化学自动审核方法、***、装置和存储介质 |
| CN112316149A (zh) * | 2020-11-11 | 2021-02-05 | 王海涛 | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2669583A (en) * | 1954-02-16 | X-amroo-zralkoxbbenzamdjes | ||
| US2006735A (en) * | 1932-11-17 | 1935-07-02 | Gen Aniline Works Inc | Nitro-aryl amino-aryl amines |
| LU38172A1 (ja) * | 1957-11-25 | |||
| US3228833A (en) * | 1962-12-17 | 1966-01-11 | Sterling Drug Inc | Anticoccidial compositions and methods of using same |
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| ES2056790T3 (es) * | 1986-01-17 | 1994-10-16 | Preventive Medicine Inst | Ensayo para determinar la predisposicion o susceptibilidad a enfermedades asociadas con dna. |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5719151A (en) * | 1990-05-04 | 1998-02-17 | Shall; Sydney | Substituted benzene compounds |
| US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
| US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
| SK283693B6 (sk) * | 1990-09-28 | 2003-12-02 | Smithkline Beecham Corporation | Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli |
| US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
| US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| US5753674A (en) * | 1991-10-22 | 1998-05-19 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents |
| US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
| US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
| US5783599A (en) * | 1993-02-24 | 1998-07-21 | Octamer Inc | Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones |
| JP3025602B2 (ja) * | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US6169104B1 (en) * | 1997-03-26 | 2001-01-02 | Large Scale Biology Corporation | Di-aryl ethers and their derivatives as anti-cancer agents |
| US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| US6235748B1 (en) * | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6514983B1 (en) * | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| US6380193B1 (en) * | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| AU764216B2 (en) * | 1998-11-27 | 2003-08-14 | Basf Aktiengesellschaft | Substituted benzimidazoles and their use as parp inhibitors |
| US6387902B1 (en) * | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| AU3076700A (en) * | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
| DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| AU2003287526A1 (en) * | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| EP1622942B1 (en) * | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| US7268138B2 (en) * | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| KR101138471B1 (ko) * | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | 트리시클로 ｐａｒｐ 저해제 |
| CN1832757A (zh) * | 2003-08-01 | 2006-09-13 | 惠氏控股公司 | 表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途 |
| WO2005023246A1 (en) * | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
| WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| ATE551345T1 (de) * | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| KR20090130156A (ko) * | 2004-09-22 | 2009-12-17 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물 |
| US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| KR20080031266A (ko) * | 2005-06-10 | 2008-04-08 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 조절제 및 암의 치료 |
| JP5177429B2 (ja) * | 2005-07-18 | 2013-04-03 | バイパー サイエンシズ，インコーポレイティド | 癌の治療 |
| DE102006037399A1 (de) * | 2006-08-10 | 2008-02-14 | Archimica Gmbh | Verfahren zur Herstellung von Arylaminen |
| US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| EP2059802A4 (en) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF |
| CN101522609A (zh) * | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
| US7994222B2 (en) * | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
| EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| CN101888777A (zh) * | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
-
2008
- 2008-11-12 CA CA2705417A patent/CA2705417A1/en not_active Withdrawn
- 2008-11-12 KR KR1020107012840A patent/KR20100102607A/ko not_active Application Discontinuation
- 2008-11-12 CN CN2008801245418A patent/CN101918003A/zh not_active Withdrawn
- 2008-11-12 US US12/269,833 patent/US20090123419A1/en not_active Abandoned
- 2008-11-12 NZ NZ586123A patent/NZ586123A/xx not_active IP Right Cessation
- 2008-11-12 AU AU2008321382A patent/AU2008321382A1/en not_active Withdrawn
- 2008-11-12 JP JP2010533126A patent/JP2011503071A/ja not_active Abandoned
- 2008-11-12 SG SG2012081592A patent/SG185954A1/en unknown
- 2008-11-12 WO PCT/US2008/012757 patent/WO2009064444A2/en active Application Filing
- 2008-11-12 EP EP08848605A patent/EP2217244A4/en not_active Withdrawn
- 2008-11-12 MX MX2010005221A patent/MX2010005221A/es unknown
-
2009
- 2009-07-14 US US12/502,943 patent/US20100009930A1/en not_active Abandoned
-
2010
- 2010-05-09 IL IL205633A patent/IL205633A0/en unknown
- 2010-05-11 TN TN2010000209A patent/TN2010000209A1/fr unknown
- 2010-05-11 NI NI201000084A patent/NI201000084A/es unknown
- 2010-05-11 GT GT201000137A patent/GT201000137A/es unknown
- 2010-05-12 DO DO2010000142A patent/DOP2010000142A/es unknown
- 2010-06-07 EC EC2010010235A patent/ECSP10010235A/es unknown
- 2010-06-10 CR CR11486A patent/CR11486A/es unknown
- 2010-06-11 MA MA32905A patent/MA32748B1/fr unknown
- 2010-06-11 CO CO10070932A patent/CO6290649A2/es not_active Application Discontinuation
-
2012
- 2012-11-16 DO DO2012000290A patent/DOP2012000290A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503071A5 (ja) | ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 | |
| IL275379B2 (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors | |
| HRP20200696T1 (hr) | Terapija u kombinaciji s inhibitorom topoizomeraze | |
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2013507415A5 (ja) | ||
| ES2389809T3 (es) | Terapias anticancerosas | |
| JP2012517427A5 (ja) | ||
| JP2016536352A5 (ja) | ||
| JP2012067116A5 (ja) | ||
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| JP2019511526A5 (ja) | ||
| AU2008270732B2 (en) | Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine | |
| JP2009515901A5 (ja) | ||
| JP2011527291A5 (ja) | ||
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| JP2008540364A5 (ja) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2014065696A5 (ja) | ||
| CN103327977A (zh) | 恶液质的治疗或预防剂 | |
| NZ598096A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| JP2015507020A5 (ja) | ||
| JP2007277240A5 (ja) | ||
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение |